TNDM - TNDM INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tandem Diabetes Care Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit | Benzinga
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") have until November 7, 2023 to seek appointment as lead plaintiff of the Tandem Diabetes class action lawsuit. Captioned Lowe v. Tandem Diabetes Care, Inc., No. 23-cv-01657 (S.D. Cal.), the Tandem Diabetes class action lawsuit charges Tandem Diabetes and certain of its top executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Tandem Diabetes class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-tandem-diabetes-care-inc-class-action-lawsuit-tndm.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.
CASE ALLEGATIONS: Tandem Diabetes is a global medical technology company that develops, manufactures, and markets a variety of consumer technologies and software for at-home diabetes care.
The Tandem Diabetes class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: ...